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BACKGROUND: Few articles have been published on the imaging findings of 
anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). 
METHODS: To investigate the radiological findings of ALK-positive NSCLC in the 
advanced stage, CT scans were examined. In addition, the response to chemotherapy 
was evaluated. 
RESULTS: Of the 36 patients with ALK-rearranged NSCLC, a mass and nodule 
were identified in 17 (47.2%) and 16 (44.4%), respectively, indicating that more than 
40% had a small-sized tumor. Overall, 31 (86.1%) patients had lymphadenopathy, 7 
(19.4%) had extranodal lymph node invasion, and 3 (8.3%) had lymphangitis. A 
pleural effusion was seen in 15 patients (41.7%). All but one patient had no 
ground-glass opacity (GGO) lesions, indicating that most ALK-positive tumors 
showed a solid growth pattern without GGO on CT. Twenty were evaluable for 
response to chemotherapy; 10 (50.0%) had a partial response (PR), 9 (45.0%) had 
stable disease (SD), and 1 (5.0%) had progressive disease (PD) with first-line 
chemotherapy. With second-line chemotherapy, 5 (26.3%) had PR, 11 (57.9%) had 
SD, and 3 (15.8%) had PD. The 5 patients with PR were all treated by crizotinib. 
Time to progression was 8.2 months with first-line chemotherapy, and 6.0 months 
with second-line chemotherapy. 
CONCLUSIONS: Advanced stage ALK-positive tumors have a relatively aggressive 
phenotype, which cannot be inferred from the size of the tumor alone. ALK-positive 
patients have a good response to first-line cytotoxic drugs and to crizotinib as 
second-line therapy, but a relatively poor response to cytotoxic drugs as second-line 
therapy. 
 
